Merus touts bispecific antibody efficacy data with a later data cut-off in uncommon NRG1+ cancers: #ESMO23

Reynald Castañeda

Deputy Editor

MADRID — Merus unveiled further efficacy data on Monday for its bispecific antibody zenocutuzumab, which further demonstrates “robust and durable” response in patients with NRG1+ non …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Merus touts bispecific antibody efficacy data with a later data cut-off in uncommon NRG1+ cancers: #ESMO23

Reynald Castañeda

Deputy Editor

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

Sanofi's BTK inhibitor again slows MS progression, but liver enzymes continue to be tricky

Lexicon's president to step down as decision date looms; Sarepta welcomes Lilly, GSK vet to board

Gilead's Kite uncouples from Fosun in China as Yescarta faces coverage obstacles

Aligos’ trial for oral MASH treatment succeeds, but placebo group shows odd trend

FDA inspectors discover trucks carrying torn-up records leaving Indian generics factory

Breaking down silos with a new quantitative approach to drug development

Merus touts bis­pe­cif­ic an­ti­body ef­fi­ca­cy da­ta with a lat­er da­ta cut-off in un­com­mon NRG1+ can­cers: #ES­MO23

Deputy Editor

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Merus touts bispecific antibody efficacy data with a later data cut-off in uncommon NRG1+ cancers: #ESMO23